Sulforaphane prevents abdominal aortic aneurysm formation through the inhibition of phenotypic switching of vascular smooth muscle cells and inflammation via the activation of Nrf2.

Abstract excerpt

OBJECTIVE: Targeted therapy for the phenotypic switching of vascular smooth muscle cell(VSMC) is a critical strategy for mitigating disease progression in patients with abdominal aortic aneurysms (AAAs). Sulforaphane (SFN), a nuclear factor E2 factor-related factor (Nrf2) activator, has anti-inflammatory and antioxidant properties and might regulate the phenotypic switching of VSMCs. However, the role of SFN in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aortic Aneurysm, Abdominal
• Share to Inflammation